Terms: = Endocrine gland cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2
76 results:
1. Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets.
Dong Z; Chong W; Chen C; Qi L; Mengke L; Minghui D; Jiawei Y; Longxi Q; Hengchao L; Liu J; Zhimin G
BMC Cancer; 2024 Mar; 24(1):286. PubMed ID: 38439030
[TBL] [Abstract] [Full Text] [Related]
2. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
[TBL] [Abstract] [Full Text] [Related]
3. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract] [Full Text] [Related]
4. Whole-exome sequencing reveals candidate high-risk susceptibility genes for endometriosis.
Nousiainen S; Kuismin O; Reinikka S; Manninen R; Khamaiseh S; Kuivalainen M; Terho A; Koivurova S; Niinimäki M; Salokas K; Varjosalo M; Ahtikoski A; Bützow R; Lindgren O; Uimari O; Vahteristo P
Hum Genomics; 2023 Oct; 17(1):88. PubMed ID: 37789421
[TBL] [Abstract] [Full Text] [Related]
5. HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation.
Chia L; Wang B; Kim JH; Luo LZ; Shuai S; Herrera I; Chen SY; Li L; Xian L; Huso T; Heydarian M; Reddy K; Sung WJ; Ishiyama S; Guo G; Jaffee E; Zheng L; Cope LM; Gabrielson K; Wood L; Resar L
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36919699
[TBL] [Abstract] [Full Text] [Related]
6. Loss of fgfr4 promotes the malignant phenotype of PDAC.
D'Agosto S; Pezzini F; Veghini L; Delfino P; Fiorini C; Temgue Tane GD; Del Curatolo A; Vicentini C; Ferrari G; Pasini D; Andreani S; Lupo F; Fiorini E; Lorenzon G; Lawlor RT; Rusev B; Malinova A; Luchini C; Milella M; Sereni E; Pea A; Bassi C; Bailey P; Scarpa A; Bria E; Corbo V
Oncogene; 2022 Sep; 41(38):4371-4384. PubMed ID: 35963908
[TBL] [Abstract] [Full Text] [Related]
7. A rare case of highly differentiated follicular carcinoma in ovary with fgfr4 Gly388Arg polymorphism: a case report and literature review.
Bao YT; Wang C; Huang W; Yao LQ; Yuan L
J Ovarian Res; 2022 Jun; 15(1):71. PubMed ID: 35701820
[TBL] [Abstract] [Full Text] [Related]
8. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma.
Tamburello M; Altieri B; Sbiera I; Sigala S; Berruti A; Fassnacht M; Sbiera S
Endocrine; 2022 Sep; 77(3):411-418. PubMed ID: 35583844
[TBL] [Abstract] [Full Text] [Related]
9. Maelstrom promotes tumor metastasis through regulation of fgfr4 and epithelial-mesenchymal transition in epithelial ovarian cancer.
He WP; Yang GP; Yang ZX; Shen HW; You ZS; Yang GF
J Ovarian Res; 2022 May; 15(1):55. PubMed ID: 35513870
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis.
Zhou C; Liu Z; Zhou Y; Ren D; Liu K; Qin G; Zhang H; Liang X; Gou S; Wu H
Can J Gastroenterol Hepatol; 2021; 2021():4350417. PubMed ID: 35047460
[TBL] [Abstract] [Full Text] [Related]
11. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.
Sbiera I; Kircher S; Altieri B; Lenz K; Hantel C; Fassnacht M; Sbiera S; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():795116. PubMed ID: 34956100
[TBL] [Abstract] [Full Text] [Related]
12. Dual inhibition of fgfr4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain.
Guo T; Gu C; Li B; Xu C
Aging (Albany NY); 2021 Aug; 13(15):19750-19759. PubMed ID: 34351305
[TBL] [Abstract] [Full Text] [Related]
13. High Prevalence of DICER1 Mutations and Low Frequency of Gene Fusions in Pediatric Follicular-Patterned Tumors of the Thyroid.
Bae JS; Jung SH; Hirokawa M; Bychkov A; Miyauchi A; Lee S; Chung YJ; Jung CK
Endocr Pathol; 2021 Sep; 32(3):336-346. PubMed ID: 34313965
[TBL] [Abstract] [Full Text] [Related]
14. Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features.
Durcan E; Keskin FE; Ozkaya HM; Sirolu S; Sahin S; Korkmaz OP; Gazioglu N; Tanriover N; Comunoglu N; Oz B; Kizilkilic O; Kadioglu P
Exp Clin Endocrinol Diabetes; 2022 Feb; 130(2):125-133. PubMed ID: 34255320
[TBL] [Abstract] [Full Text] [Related]
15. Genomic relevance of FGF14 and associated genes on the prognosis of pancreatic cancer.
Raja A; Malik MFA; Haq F
PLoS One; 2021; 16(6):e0252344. PubMed ID: 34061869
[TBL] [Abstract] [Full Text] [Related]
16. Up-to-date comparison of robotic-assisted versus open distal pancreatectomy: A PRISMA-compliant meta-analysis.
Zhou J; Lv Z; Zou H; Xiong L; Liu Z; Chen W; Wen Y
Medicine (Baltimore); 2020 Jun; 99(23):e20435. PubMed ID: 32501990
[TBL] [Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
Bogani G; Ditto A; Lopez S; Bertolina F; Murgia F; Pinelli C; Chiappa V; Raspagliesi F
Gynecol Oncol; 2020 Apr; 157(1):293-298. PubMed ID: 31980220
[TBL] [Abstract] [Full Text] [Related]
18. Fibroblast growth factor receptor 4 (fgfr4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.
Heublein S; Anglesio MS; Marmé F; Kommoss S
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2251-2259. PubMed ID: 31385026
[TBL] [Abstract] [Full Text] [Related]
19. Dysregulation in IGF-1R, fgfr4 and βKlotho signaling in patients with medullary thyroid cancer.
Motylewska E; Borkowska M; Ławnicka H; Kuzdak K; Siejka A; Świętosławski J; Stepien H; Stepien T
Neuro Endocrinol Lett; 2019 Mar; 40(1):29-35. PubMed ID: 31184820
[TBL] [Abstract] [Full Text] [Related]
20. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract] [Full Text] [Related]
[Next]
